Updated:
Acorn Bioventures
Acorn Bioventures focuses on investments in private and small-capitalization biotech, specialty pharma, and medical device companies. The firm has made 27...
Overview
Acorn Bioventures focuses on investments in private and small-capitalization biotech, specialty pharma, and medical device companies. The firm has made 27 investments, including a Series D investment in Neuron23 on June 24, 2025. Acorn Bioventures has facilitated 9 portfolio exits, with Verona Pharma being their most recent exit on October 07, 2025.
General information
Firm type
Venture Capital
Year founded
2017
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Sector focus
Frequently asked questions
What stages does Acorn Bioventures target?
The firm lists coverage of seed, expansion, late-stage growth, PIPEs, and pre-IPO transactions.
Where is Acorn Bioventures headquartered?
New York, United States.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: